TCAR Achieves Favorable Outcomes vs. Carotid Endarterectomy in Patients with Carotid Artery Disease

B2B Training: What’s the Most Effective Way of Learning?

B2B training, which is short for business-to-business training, is a popular and convenient type of training that enables entire companies to train their teams...

AlixPartners Forecasts: Household Products Could Cost U.S. Manufacturers and Consumers 15% More This Year Due to Resin Shortage

While companies can’t control the market forces at play, they can take action to mitigate the risk and impact of supply chain disruption.

Silk Road Medical, Inc. (SILK), a company focused on reducing the risk of stroke and its devastating impact, today announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at the Society for Vascular Surgery 2019 Vascular Annual Meeting (VAM). In a headline presentation, Dr. Mahmoud Malas of the University of California, San Diego School of Medicine shared updated results for the ongoing TransCarotid Artery Revascularization (TCAR) Surveillance Project.

“The results of the TCAR Surveillance Project are overwhelmingly positive on a large dataset of patients, showing, for the first time, significantly lower odds of composite in-hospital stroke, death and myocardial infarction compared to CEA. TCAR had statistically equivalent in-hospital stroke and death rates as CEA, with significantly lower odds of myocardial infarction and cranial nerve injury. Additionally, there was a significant reduction in mortality at 30 days and 1 year, likely attributable to the reduction in myocardial infarction,” Dr. Malas said. “Patients clearly benefit from TCAR’s less-invasive approach and with these data and future studies with similar results, I believe TCAR may become the standard of care.”

The presentation, “Outcomes of Transcarotid Revascularization with Dynamic Flow Reversal Versus Carotid Endarterectomy in the Transcarotid Revascularization Surveillance Project,” evaluated patients between 2015 and 2018, with 5,716 patients receiving TCAR compared to 44,442 patients receiving carotid endarterectomy (CEA), with 5,160 patients in each group analyzed using propensity score matching. There were no statistical differences noted between TCAR and CEA for in-hospital stroke (odds ratio (OR) 0.80, p=0.19) or in-hospital stroke and death (OR: 0.77, p=0.09).  Other key findings for TCAR compared to CEA include:

  • 59% lower odds of in-hospital myocardial infarction (OR: 0.41, p<.001)
  • 87% lower odds of in-hospital cranial nerve injury (OR: 0.13, p<0.001)
  • 35% lower odds of in-hospital stroke, death and myocardial infarction (OR: 0.65, p<.01)
  • 26% lower odds of hospital stay longer than 1 day (OR: 0.74, p<0.001)
  • 25% lower odds of non-home discharge (OR: 0.75, p<0.001)

In a separate risk adjusted analysis looking at 30-day and 1 year follow up, the results were as follows:

  • 34% lower odds of 30-day death (OR: 0.66, p=0.03)
  • 46% lower odds of 30-day stroke and death (OR: 0.54, p=0.02)
  • 53% lower odds of 30-day stroke, death and MI (OR: 0.47, p<0.01)
  • 23% lower odds of 1-year mortality (OR: 0.77, p=0.02)

“These updated data from the TCAR Surveillance Project mark a major milestone in our journey to build the clinical evidence base,” said Erica Rogers, Chief Executive Officer. “As these results are proven on ever larger numbers of patients, we are seeing the continued impact of our relentless focus on patient outcomes which we believe is key to driving durable and growing adoption of TCAR in the long run.”

The TCAR Surveillance Project, a key initiative of the Society for Vascular Surgery’s Vascular Quality Initiative (VQI), is an open-ended registry intended to compare real-world patient outcomes between TCAR and CEA.



Mediclinic Appoints 2 New Independent Non-Executive Directors

Natalia Barsegiyan and Zarina Bassa will bring significant and diverse skills and experience, complementing those of existing Board members. I am confident they will both be great additions to our Board of Directors.”

Asensus Surgical Appoints Two New Board Members

Asensus Surgical, Inc. (NYSE American: ASXC), a medical device company that is digitizing the interface between the surgeon and the patient to pioneer a new era of Performance-Guided Surgery™, today announced the expansion of its Board of Directors, appointing...

Our Sister Publication: Biotechnology News Magazine

Subscribe to Medical Device News Magazine here.